If gastrointestinal symptoms are interfering with daily life, your prescriber might pause or slow your dose escalation schedule
The Noom, a well-established digital healthcare company focused on chronic disease prevention and encouraging people to live a quality and longer life, launched the Noom microdose GLP-1program, a commendable initiative providing long-term health and weight-loss benefits with fewer side effects via personalized microdoses of GLP-1 medication, in clinical accuracy cases
Exciting news alert
Here is the most important takeaway: As of late 2025, there are no FDA-approved GLP-1 medication patches (semaglutide, tirzepatide, or others) commercially available from a legitimate pharmacy
The warning also notes that serious neuropsychiatric issues linked to bupropion have been reported
FDA adverse event reporting system analysis The most comprehensive look at GLP-1 hair loss comes from analysis of the FDA Adverse Event Reporting System, known as FAERS